Sutro Biopharma raises $110M in underwritten public offering of 7.87M shares at $13.98/share

SUTRO BIOPHARMA, INC.

Offering of 7,868,383 shares at $13.98 per share; gross proceeds approximately $110.0 million.
Underwriters include Leerink Partners and TD Securities; closing expected February 11, 2026.
Proceeds to fund research, clinical development, manufacturing, and general corporate purposes.
Combined with existing cash, total capital resources estimated at $251.4 million; cash runway into Q2 2028.
Offering made under existing shelf registration statement; customary underwriting agreement terms.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SUTRO BIOPHARMA, INC. entered into Underwriting Agreement with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein valued at approximately $110.0 million (effective 2026-02-09).

Action: entry
Agreement: underwriting
Counterparty: Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein
Value: approximately $110.0 million
Effective: 2026-02-09

Exact text from the filing

On February 9, 2026, Sutro Biopharma, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein

View on SEC.gov

280 material agreements filed in the last 30 days. Browse all material agreements →

SUTRO BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-044934

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.